Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
347.96B
Market cap347.96B
Price-Earnings ratio
113.36
Price-Earnings ratio113.36
Dividend yield
2.40%
Dividend yield2.40%
Average volume
11.23M
Average volume11.23M
High today
$143.45
High today$143.45
Low today
$139.21
Low today$139.21
Open price
$140.00
Open price$140.00
Volume
8.24M
Volume8.24M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$82.01
52 Week low$82.01

Stock Snapshot

With a market cap of 347.96B, Merck(MRK) trades at $143.33. The stock has a price-to-earnings ratio of 113.36 and currently yields dividends of 2.40%.

On 2026-10-29, Merck(MRK) stock traded between a low of $139.21 and a high of $143.45. Shares are currently priced at $143.33, which is +3.0% above the low and -0.1% below the high.

Merck(MRK) shares are trading with a volume of 8.24M, against a daily average of 11.23M.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

MRK News

Investing.com 14h
Merck in focus: Earnings loom as investors eye 2027 outlook By Investing.com - Investing.com

...

Merck in focus: Earnings loom as investors eye 2027 outlook By Investing.com - Investing.com
Seeking Alpha 15h
Pharma giants Merck, Eli Lilly face earnings health check

Pharmaceutical giants Merck (MRK) and Eli Lilly (LLY) are scheduled to report third-quarter results on October 29, with analysts expecting a year-on-year earnin...

Pharma giants Merck, Eli Lilly face earnings health check
Zacks 19h
Brokers Suggest Investing in Merck: Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brok...

Brokers Suggest Investing in Merck: Read This Before Placing a Bet

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

Simply Wall St 1d
Could Merck Reset Endometrial Cancer Care With Two Phase 3 Wins?

Merck (NYSE:MRK) reported new Phase 3 data for sacituzumab tirumotecan and KEYTRUDA in advanced or recurrent endometrial cancer, highlighted at a major oncology...

Benzinga 3d
Merck Endometrial Cancer Studies Show Significant Survival Gains

Merck & Co. Inc. (NYSE:MRK) on Monday announced results from two late-stage clinical studies evaluating treatments for advanced or recurrent endometrial cancer...

Merck Endometrial Cancer Studies Show Significant Survival Gains
Zacks 3d
Countdown to Merck Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

The upcoming report from Merck (MRK Quick QuoteMRK - Free Report) is expected to reveal quarterly earnings of $2.12 per share, indicating a decline of 17...

Countdown to Merck Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Simply Wall St 4d
What Merck's Melanoma Vaccine Trial Win Means For Shareholders

Merck and Moderna reported detailed Phase 3 INTerpath-001 results showing that personalized mRNA therapy intismeran plus Keytruda cut recurrence or death risk b...

Simply Wall St 5d
Merck Stock May Be 38% Undervalued Following Melanoma Vaccine Results

has delivered a powerful multi year share price run and a packed oncology news flow, which naturally raises a simple question for you as an investor. Is the cur...

24/7 Wall St. 5d
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

Investing AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? When a drugmaker's top product loses patent protection, the dividend usually...

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?
MarketWatch 6d
The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

Moderna and Merck proved their custom cancer vaccine cut the risk of melanoma returning for longer than the cancer drug Keytruda, but it may take several years...

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.